Caricamento...
Cancer therapeutic antibodies come of age: Targeting minimal residual disease
Ten years after the first clinical application of Rituximab, an anti‐CD20 recombinant monoclonal antibody, immunotherapy has become common practice in oncology wards. Thanks to the great diversity of the immune system and the powerful methodology of genetic engineering, the pharmacologic potential o...
Salvato in:
| Pubblicato in: | Mol Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2007
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5543854/ https://ncbi.nlm.nih.gov/pubmed/19383286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2007.01.003 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|